-- ============================================================================
-- SURGERY 3 MCQ BATCH 45: Skin and Soft Tissue Surgery (Questions 2641-2700)
-- Topic: Skin Cancer, Melanoma, Soft Tissue Sarcoma, Burns
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Skin Cancer (1-15)
('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The most common skin cancer is:',
'Melanoma', 'Basal cell carcinoma (BCC), accounting for approximately 80% of non-melanoma skin cancers', 'Squamous cell carcinoma', 'Merkel cell carcinoma', 'Kaposi sarcoma',
'B', 'Basal cell carcinoma: most common skin cancer and most common human malignancy. Risk factors: UV exposure (cumulative), fair skin, immunosuppression. Characteristics: slow-growing, locally invasive, rarely metastasizes (less than 0.5%). Types: nodular (most common - pearly papule with telangiectasia), superficial, morpheaform (infiltrative, worst prognosis). Location: sun-exposed areas (face 80%). Treatment: excision, Mohs for high-risk/facial, topical for superficial. Reference: Cameron MC. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Squamous cell carcinoma (SCC) of the skin differs from BCC by:',
'Never metastasizing', 'Having higher metastatic potential (2-5%), often arising in sun-damaged or scarred skin', 'Being benign', 'Only affecting elderly', 'Always being pigmented',
'B', 'SCC vs BCC: (1) Metastatic potential: SCC 2-5% (higher in immunosuppressed, chronic wounds, Marjolin ulcer), BCC rare. (2) Appearance: SCC - keratotic, ulcerated, firm; BCC - pearly, translucent. (3) Location: both sun-exposed, but SCC more common on lips, ears, hands. (4) Precursors: SCC from actinic keratosis, SCC in situ (Bowen disease); BCC less defined precursor. High-risk SCC: greater than 2 cm, poorly differentiated, perineural invasion, immunosuppression. Treatment: excision with clear margins, consider SLN for high-risk. Reference: Thompson AK. JAAD. 2016.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Mohs micrographic surgery is particularly indicated for:',
'All skin cancers', 'High-risk non-melanoma skin cancers in cosmetically sensitive areas (face, ears) requiring tissue conservation', 'Melanoma', 'Distant metastases', 'Superficial BCC on trunk',
'B', 'Mohs surgery: technique with intraoperative margin assessment. Process: remove thin layer, map and examine 100% of margins, repeat until clear. Indications: (1) High-risk location (face, especially periorbital, nasal, ears), (2) Large or recurrent tumors, (3) Aggressive histology (morpheaform BCC, poorly differentiated SCC), (4) Perineural invasion, (5) Tissue conservation needed. Advantages: highest cure rate (99% primary BCC), maximum tissue sparing. Not indicated for melanoma (different margin requirements). Reference: Ad Hoc Task Force. JAAD. 2012.',
'medium', 'knowledge'),

-- Melanoma (16-35)
('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The ABCDE criteria for melanoma detection include:',
'Age, Bleeding, Color, Diameter, Evolution', 'Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, and Evolution/change over time', 'Antibiotics, Biopsy, CT, Dermatoscopy, Excision', 'Only size matters', 'Pain assessment',
'B', 'ABCDE criteria: clinical features suggestive of melanoma. (A) Asymmetry: one half does not match other. (B) Border: irregular, scalloped, poorly defined. (C) Color: varied (brown, black, red, white, blue). (D) Diameter: greater than 6 mm (pencil eraser). (E) Evolution: changing in size, shape, or color. Additional: ugly duckling sign (lesion different from others). Any suspicious lesion requires biopsy. Nodular melanoma may not follow ABCDE (symmetric, regular, uniform). Reference: Friedman RJ. CA Cancer J Clin. 1985.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The most important prognostic factor in localized melanoma is:',
'Location', 'Breslow thickness (depth of invasion in millimeters)', 'Color', 'Patient age', 'Gender',
'B', 'Breslow thickness: measured from granular layer of epidermis to deepest tumor cell. Most important prognostic factor for localized melanoma. Staging: T1 (1.0 mm or less), T2 (1.01-2.0), T3 (2.01-4.0), T4 (greater than 4.0). Other factors: ulceration, mitotic rate, lymph node status. 5-year survival: thin melanoma (less than 1 mm) greater than 95%, thick (greater than 4 mm) approximately 50%. Determines surgical margin width and need for sentinel node biopsy. Reference: Gershenwald JE. CA Cancer J Clin. 2017 (AJCC 8th).',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Recommended excision margins for melanoma depend on thickness. For 1.01-2.0 mm melanoma, the margin is:',
'0.5 cm', '1-2 cm (typically 1 cm adequate based on trials)', '3 cm', '5 cm', 'No margin needed',
'B', 'Melanoma excision margins (based on Breslow thickness): In situ: 0.5-1 cm. Less than 1 mm: 1 cm. 1.01-2.0 mm: 1-2 cm. Greater than 2 mm: 2 cm. Trials (Swedish, UK, Intergroup): no survival benefit for wider margins than recommended. Deep margin: to fascia (not including fascia). Wide local excision after initial diagnostic biopsy. Primary closure when possible. Reference: Sladden MJ. Cochrane Database. 2009.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Sentinel lymph node biopsy (SLNB) in melanoma is indicated for:',
'All melanomas', 'Melanomas greater than 0.8 mm thickness (or less than 0.8 mm with ulceration or high mitotic rate) with clinically negative nodes', 'Only metastatic disease', 'In situ melanoma', 'When nodes are clinically positive',
'B', 'SLNB indications in melanoma: (1) Breslow greater than 0.8 mm, (2) Breslow less than 0.8 mm with ulceration or high mitotic rate, (3) Clinically node-negative. Purpose: staging (most important prognostic factor after thickness), guides adjuvant therapy. Technique: lymphoscintigraphy, blue dye and/or radiotracer. Positive SLN: proceed to adjuvant therapy (immunotherapy, targeted if BRAF+). MSLT-II trial: completion lymph node dissection not required for positive SLN, observation with ultrasound acceptable. Reference: Morton DL. N Engl J Med. 2006.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'BRAF mutations occur in approximately what percentage of melanomas?',
'5%', '40-50% of melanomas carry BRAF mutations, most commonly V600E', '90%', '1%', 'BRAF is never mutated',
'B', 'BRAF mutations in melanoma: (1) Prevalence: 40-50% of cutaneous melanomas. (2) Most common: V600E (80% of BRAF mutations), V600K. (3) More common in: younger patients, superficial spreading type, non-chronic sun damage sites. (4) Treatment: BRAF + MEK inhibitors (dabrafenib + trametinib, encorafenib + binimetinib) - high response rates in advanced disease. (5) Testing: mandatory for Stage III-IV melanoma. Immunotherapy (checkpoint inhibitors) also highly effective regardless of BRAF status. Reference: Davies H. Nature. 2002.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Immune checkpoint inhibitors for advanced melanoma include:',
'Traditional chemotherapy', 'PD-1 inhibitors (pembrolizumab, nivolumab) and CTLA-4 inhibitors (ipilimumab)', 'Antibiotics', 'Steroids', 'Hormone therapy',
'B', 'Immunotherapy in melanoma: (1) PD-1 inhibitors: pembrolizumab, nivolumab - first-line for advanced melanoma, also adjuvant. (2) CTLA-4 inhibitor: ipilimumab - can combine with PD-1. (3) Combination nivo + ipi: higher response (60%) but more toxicity. (4) Benefits: durable responses, some complete remissions. (5) Toxicities: immune-related AEs (colitis, pneumonitis, hepatitis, endocrinopathies). Revolutionized melanoma treatment - 5-year survival improved from 10% to 40-50% in metastatic disease. Reference: Robert C. N Engl J Med. 2015.',
'medium', 'knowledge'),

-- Soft Tissue Sarcoma (36-50)
('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Soft tissue sarcomas most commonly present as:',
'Painful mass', 'Painless, enlarging soft tissue mass, often discovered incidentally or when large', 'Skin rash', 'Weight loss first', 'Fever',
'B', 'STS presentation: (1) Painless mass (most common - 50-70% painless initially). (2) Growing mass. (3) Often deep to fascia. (4) May present late (when large or symptomatic). (5) Approximately 50% in extremities (thigh most common site). Pain: may indicate high-grade or nerve involvement. Concerning features: greater than 5 cm, deep, growing, firm/fixed. Any soft tissue mass meeting these criteria needs MRI and biopsy before excision. Reference: Brennan MF. Ann Surg. 2014.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The most common histologic subtype of soft tissue sarcoma in adults is:',
'Liposarcoma and leiomyosarcoma', 'Undifferentiated pleomorphic sarcoma (formerly MFH) and liposarcoma are among the most common', 'Osteosarcoma', 'Ewing sarcoma', 'Rhabdomyosarcoma',
'B', 'STS subtypes: More than 70 histologic types. Most common in adults: (1) Undifferentiated pleomorphic sarcoma (UPS/formerly MFH), (2) Liposarcoma (several subtypes with different behavior), (3) Leiomyosarcoma, (4) Synovial sarcoma (younger adults), (5) Gastrointestinal stromal tumor (GIST - if included). Pediatric: rhabdomyosarcoma most common. Histologic grade: most important prognostic factor (French/FNCLCC system). Reference: WHO Classification of Soft Tissue Tumours.',
'hard', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The imaging modality of choice for evaluating soft tissue sarcoma is:',
'Plain X-ray', 'MRI with contrast for local staging, CT chest for lung metastases', 'Ultrasound only', 'PET only', 'No imaging needed',
'B', 'STS imaging: (1) MRI: best for local staging, defines relationship to neurovascular structures, muscle compartments, extent. Use contrast. (2) CT chest: STS spreads hematogenously to lungs primarily. Staging CT abdomen if retroperitoneal/pelvic tumor. (3) CT for retroperitoneal tumors. (4) PET-CT: can help assess grade, detect metastases, not routine for all STS. Always image before biopsy (biopsy can obscure anatomy). Reference: NCCN Soft Tissue Sarcoma Guidelines.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Biopsy for suspected soft tissue sarcoma should be:',
'Excisional for all', 'Core needle biopsy (preferred) or incisional biopsy placed in line with planned definitive resection incision', 'Shave biopsy', 'No biopsy needed', 'Fine needle aspiration only',
'B', 'STS biopsy principles: (1) Core needle biopsy: preferred, adequate tissue for histology and molecular testing. (2) Incisional biopsy: if core inadequate, orient longitudinally for extremity lesions. (3) Critical: biopsy tract must be excisable with definitive resection. (4) Avoid: transverse incisions on extremities, contaminating multiple compartments, hematoma. (5) Should be performed at or in consultation with treating sarcoma center. (6) Excisional biopsy: only for small (less than 3 cm) superficial lesions. Reference: Mankin HJ. J Bone Joint Surg. 1996.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The goal of surgery for soft tissue sarcoma is:',
'Marginal excision', 'Wide local excision with negative microscopic margins (R0 resection), limb-sparing when possible', 'Debulking only', 'Amputation always', 'No surgery',
'B', 'STS surgical principles: (1) Wide excision: tumor with cuff of normal tissue (1-2 cm or anatomic barrier). (2) R0 resection: negative microscopic margins - primary goal. (3) Limb-sparing: possible in greater than 90% of extremity STS with neoadjuvant radiation. (4) Amputation: only when limb-sparing not possible with acceptable function. (5) Critical structures: may need vascular reconstruction, nerve grafts. (6) Multidisciplinary planning essential. Margin status: strongest local recurrence predictor. Reference: Pisters PW. J Clin Oncol. 1996.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Radiation therapy in soft tissue sarcoma:',
'Is never used', 'Reduces local recurrence when combined with limb-sparing surgery, can be given neoadjuvantly or adjuvantly', 'Replaces surgery', 'Only for metastases', 'Increases amputation rate',
'B', 'Radiation in STS: (1) Combined with surgery: reduces local recurrence from 30% to less than 10%. (2) Neoadjuvant: smaller field, lower dose, but higher wound complications. (3) Adjuvant: lower wound complications, larger field, higher dose. (4) Indications: intermediate/high-grade tumors greater than 5 cm, close/positive margins. (5) May be omitted: small (less than 5 cm), low-grade, wide margins. Enables limb-sparing surgery. Reference: Yang JC. J Clin Oncol. 1998.',
'medium', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'GIST (gastrointestinal stromal tumor) is characterized by:',
'Epithelial origin', 'Origin from interstitial cells of Cajal, c-KIT mutation in majority, and response to imatinib', 'Lymph node spread', 'Never metastasizes', 'Radiation-sensitive',
'B', 'GIST: most common mesenchymal tumor of GI tract. Features: (1) Origin: interstitial cells of Cajal (pacemaker cells). (2) Mutations: c-KIT (80-85%), PDGFRA (5-10%), wild-type. (3) Location: stomach (60%), small intestine (30%). (4) Presentation: GI bleeding, mass, obstruction. (5) Diagnosis: CD117 (c-KIT) positive on IHC. (6) Treatment: surgical resection, imatinib (TKI) for unresectable/metastatic and adjuvant for high-risk. (7) Risk stratification: size, mitotic rate, location. Reference: Joensuu H. N Engl J Med. 2012.',
'medium', 'knowledge'),

-- Burns (51-60)
('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Second-degree (partial thickness) burns are characterized by:',
'Charred appearance', 'Involvement of epidermis and varying depth of dermis, blistering, painful to touch', 'No pain', 'No blisters', 'White leathery appearance',
'B', 'Burn depth: (1) Superficial (1st degree): epidermis only, red, painful, no blisters (sunburn). (2) Superficial partial (2nd): epidermis + upper dermis, blisters, very painful, moist, blanches - heals in 2-3 weeks. (3) Deep partial: into reticular dermis, mottled, less sensation, may need grafting. (4) Full thickness (3rd): entire dermis, white/charred, leathery, insensate, requires grafting. (5) 4th degree: into muscle, bone. Reference: American Burn Association.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The Rule of Nines in burn assessment estimates that the anterior trunk represents:',
'9% TBSA', '18% total body surface area (TBSA)', '36% TBSA', '1% TBSA', '27% TBSA',
'B', 'Rule of Nines (adults): Head/neck: 9%. Each upper extremity: 9%. Anterior trunk: 18%. Posterior trunk: 18%. Each lower extremity: 18%. Perineum: 1%. Modifications in children: larger head proportion (18% in infant), smaller legs. Alternative: Lund-Browder chart (more accurate, accounts for age). Palm of patient hand (including fingers) = approximately 1% TBSA - useful for scattered burns. Reference: American Burn Association.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'The Parkland formula for fluid resuscitation in major burns calculates:',
'1 mL/kg/% TBSA in 24 hours', '4 mL/kg/% TBSA of lactated Ringer in first 24 hours, with half given in first 8 hours', '10 mL/kg/hour', 'Normal saline only', 'Colloid immediately',
'B', 'Parkland formula: 4 mL x weight (kg) x %TBSA of burns. First 24 hours: half in first 8 hours (from time of burn, not admission), half in next 16 hours. Fluid: lactated Ringer (crystalloid). Goal: urine output 0.5-1 mL/kg/hr (adults), 1 mL/kg/hr (children). Formula is starting point - titrate to urine output. Avoid over-resuscitation (edema, abdominal compartment syndrome). Colloids: may add after 24 hours. Reference: Baxter CR. Surg Clin North Am. 1978.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Inhalation injury in burn patients is suggested by:',
'Burns on extremities', 'Facial burns, singed nasal hairs, carbonaceous sputum, hoarseness, and history of closed-space fire', 'Clear lungs only', 'No symptoms', 'Only on chest X-ray',
'B', 'Inhalation injury indicators: (1) History: closed-space fire/explosion. (2) Physical: facial burns, singed nasal hairs/eyebrows, carbonaceous sputum, soot in oropharynx. (3) Symptoms: hoarseness, stridor, wheezing, dyspnea. (4) Diagnosis: bronchoscopy (gold standard) - mucosal edema, soot, erythema. (5) Early intubation if suspected (edema progresses). (6) Increases fluid requirements by 30-40%. (7) Associated with CO and cyanide poisoning. (8) Major contributor to mortality. Reference: Shirani KZ. Ann Surg. 1987.',
'easy', 'knowledge'),

('c0000060-0000-0000-0000-000000000060', 'a0000003-0000-0000-0000-000000000003',
'Escharotomy is indicated for:',
'Superficial burns', 'Circumferential full-thickness burns causing vascular compromise or respiratory restriction', 'All burns', 'Pain control', 'Infection prevention',
'B', 'Escharotomy: emergency decompressive procedure. Indication: circumferential full-thickness burns with compartment syndrome (limb) or chest restriction (respiratory). Signs: decreased pulses, cyanosis, paresthesias, increasing ventilatory pressures. Technique: full-thickness incision through eschar to subcutaneous fat, along mid-lateral or mid-medial lines of extremity, bilateral chest/abdomen if needed. Does not require anesthesia (insensate). Fasciotomy may be needed if deep burns or delayed presentation. Reference: Orgill DP. N Engl J Med. 2009.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 45 (Skin and Soft Tissue Surgery): 60 questions inserted' as status;
